Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles

The Journal of Antimicrobial Chemotherapy
D M LivermoreBSAC Resistance Surveillance Standing Committee

Abstract

We assessed the activity of ceftolozane/tazobactam against consecutive isolates collected in the BSAC Bacteraemia Surveillance from 2011 to 2015 and against 'problem' isolates sent to the UK national reference laboratory from July 2015, when routine testing began. Susceptibility testing was by BSAC agar dilution with resistance mechanisms identified by PCR and interpretive reading. Data were reviewed for 6080 BSAC surveillance isolates and 5473 referred organisms. Ceftolozane/tazobactam had good activity against unselected ESBL producers in the BSAC series, but activity was reduced against ertapenem-resistant ESBL producers, which were numerous among reference submissions. AmpC-derepressed Enterobacter spp. were widely resistant, but Escherichia coli with raised chromosomal AmpC frequently remained susceptible, as did Klebsiella pneumoniae with acquired DHA-1-type AmpC. Carbapenemase-producing Enterobacteriaceae were mostly resistant, except for ceftazidime-susceptible isolates with OXA-48-like enzymes. Ceftolozane/tazobactam was active against 99.8% of the BSAC Pseudomonas aeruginosa isolates; against referred P. aeruginosa it was active against 99.7% with moderately raised efflux, 94.7% with strongly raised efflux and 96.6% w...Continue Reading

References

Dec 1, 1991·The Journal of Antimicrobial Chemotherapy·G Bonfiglio, D M Livermore
Feb 1, 1990·The Journal of Antimicrobial Chemotherapy·M AkovaD M Livermore
Jun 1, 1984·Journal of Medical Microbiology·R J WilliamsJ D Williams
Mar 3, 1999·The Journal of Antimicrobial Chemotherapy·G BonfiglioG Nicoletti
Jun 23, 2001·The Journal of Antimicrobial Chemotherapy·D M LivermoreK P Shannon
Oct 20, 2001·Pathologie-biologie·J D CavalloUNKNOWN Group d'Etude le la Resistance de P aeruginosa aux Bêtalactamines
Feb 2, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David M Livermore
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Oct 10, 2008·The Journal of Antimicrobial Chemotherapy·Rosy ReynoldsUNKNOWN BSAC Working Parties on Resistance Surveillance
May 12, 2009·International Journal of Antimicrobial Agents·David M LivermoreMarina Warner
Dec 17, 2009·Antimicrobial Agents and Chemotherapy·Krisztina M Papp-WallaceRobert A Bonomo
Mar 2, 2011·Antimicrobial Agents and Chemotherapy·Gabriel CabotUNKNOWN Spanish Network for Research in Infectious Diseases (REIPI)
May 30, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael S Gelfand, Kerry O Cleveland
Jul 15, 2015·The Annals of Pharmacotherapy·Allana J SucherMatthew Fete
May 22, 2016·Infectious Disease Clinics of North America·Krisztina M Papp-Wallace, Robert A Bonomo
Dec 14, 2016·Antimicrobial Agents and Chemotherapy·Juan José CastónJulián Torre-Cisneros

❮ Previous
Next ❯

Citations

Mar 2, 2018·Expert Review of Anti-infective Therapy·Daniele Roberto GiacobbeUNKNOWN ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva)
Jun 14, 2019·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Leandro Reus Rodrigues Perez
Apr 30, 2019·The Journal of Antimicrobial Chemotherapy·Carolyne HornerUNKNOWN BSAC Resistance Surveillance Standing Committee
Jan 18, 2018·Current Opinion in Infectious Diseases·Matteo BassettiMaddalena Peghin
Dec 14, 2019·Current Opinion in Infectious Diseases·David L PatersonPatrick N A Harris
Jan 15, 2020·Antimicrobial Agents and Chemotherapy·Sarah C J JorgensenMichael J Rybak
Aug 15, 2018·Antimicrobial Agents and Chemotherapy·Adam StewartDavid Paterson
Sep 30, 2017·The Journal of Antimicrobial Chemotherapy·Frieder SchaumburgEvgeny A Idelevich
Jun 8, 2018·Current Infectious Disease Reports·Lynn NguyenConan MacDougall
Jul 27, 2018·Open Forum Infectious Diseases·Jeanne B ForresterJohn A Bosso
Jun 28, 2019·Frontiers in Public Health·Ilias KaraiskosGaryphallia Poulakou
Dec 7, 2019·Antimicrobial Resistance and Infection Control·Almudena BurilloEmilio Bouza
Mar 28, 2020·Expert Opinion on Pharmacotherapy·Ibai Los-ArcosBenito Almirante
Dec 12, 2017·The Journal of Antimicrobial Chemotherapy·David M LivermoreNeil Woodford
Jul 17, 2018·Frontiers in Microbiology·Marie-Helene Nicolas-ChanoineJean-Marie Pagès
Dec 4, 2020·Expert Review of Anti-infective Therapy·Marios KarvouniarisGaryphallia Poulakou
Nov 18, 2020·Antimicrobial Agents and Chemotherapy·Damien FournierUNKNOWN GERPA Study Group
Nov 6, 2020·The Journal of Antimicrobial Chemotherapy·Shazad MushtaqDavid M Livermore
Nov 16, 2018·Indian Journal of Medical Microbiology·Agila Kumari PragasamKeith S Kaye
Nov 13, 2020·Clinical Microbiology Reviews·Dafna YahavLeonard Leibovici
Mar 16, 2021·International Journal of Antimicrobial Agents·Shazad MushtaqDavid M Livermore
Apr 3, 2021·Open Forum Infectious Diseases·Delaney E HartUNKNOWN C/T Alliance to deliver Real-world Evidence (CARE)
Apr 4, 2021·Journal of Clinical Medicine·Erlangga YusufMireille van Westreenen
Apr 15, 2021·Expert Opinion on Pharmacotherapy·Rita Murri, Emilio Sacco
May 21, 2021·Infectious Diseases Now·Bernard CastanD Boutoille
May 28, 2021·Clinical Microbiology Reviews·Joanna S Brooke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.